H.C. Wainwright reiterates a Buy rating on MannKind (MNKD) with a $9 price target saying it views the scPharmaceuticals (SCPH) acquisition positively. MannKind shares will benefit from a more diversified revenue base and the company paid a “very reasonable” price to acquire scPharmaceuticals, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- H.C. Wainwrights positive on MannKind deal for scPharmaceuticals
- Keurig Dr Pepper buys JDE Peet’s, Thoma Bravo to acquire Verint: Morning Buzz
- MannKind’s Strategic Acquisition of scPharmaceuticals: A Catalyst for Future Growth and Value Creation
- MannKind’s Strategic Acquisition and Growth Prospects: A Buy Rating by Yun Zhong
- MannKind Announces Acquisition of scPharmaceuticals